Medicines for mothers and children
Improving the health of mothers and children is a global priority. 5.9 million children and more than 300 000 women died in 2015 from maternal causes. Many of these deaths could have been prevented or treated with access to appropriate, affordable medicines.
WHO assists countries in improving access to and use of appropriate medicines for mothers and children by identifying research gaps, promoting appropriate selection, addressing supply and distribution inefficiencies and promoting specific regulatory measures.
Paediatric medicines Regulators' Network (PmRN)
The lack of suitable paediatric medicines, paired with inconsistent regulatory frameworks, poses significant risks to a particularly vulnerable patient population. A Paediatric medicines Regulator's Network (PmRN) has been set up with representatives from national medicines regulatory authorities (NMRAs) from all regions to provide a forum of discussion and facilitate collaboration.
Improving access to tuberculosis medicines for children
Integrating medicines into country supply chains needs careful preparation and planning to ensure the delivery of a continuous supply of quality medicines. Special measures are needed when transitioning from old to new formulations to avoid medicine confusion. Since the development of the new high-quality fixed-dose combinations of TB medications, WHO has been working together with partners to ensure the smooth transition to the new formulation in countries’ national tuberculosis programmes.
Policy, Access and Use
Essential Medicines and Health Products